In a groundbreaking medical advancement, Israel is poised to conduct the world’s inaugural human spinal cord implant. This pioneering surgery, utilizing a patient’s own cells, aims to enable paralyzed individuals to stand and walk once more. Tel Aviv University, in collaboration with the Israeli biotech company Matricelf, announced this significant milestone in regenerative medicine. This procedure represents a beacon of hope for millions globally suffering from spinal cord injuries.
Current Landscape of Spinal Cord Injuries
Globally, over 15 million people live with spinal cord injuries, often resulting from trauma such as falls, road accidents, or violence. Presently, complete cures for these injuries remain elusive. Treatment primarily focuses on stabilizing the patient, preventing further damage, and maximizing existing function. Emergency care frequently involves immobilizing the spine, reducing inflammation, and sometimes includes surgery to repair fractures or alleviate pressure. Furthermore, rehabilitation encompasses physical and occupational therapy, alongside assistive devices like wheelchairs and braces. While experimental therapies, including stem cells and robotic devices, are under exploration, no existing treatment consistently restores full spinal cord function. Indeed, the spinal cord is one of the few human tissues unable to naturally heal itself; it is both structurally complex and exceptionally sensitive. Consequently, when trauma, such as a car accident or a fall, severs the spinal cord, it breaks the vital connection between the brain and the body, leading to paralysis below the injury site.
The Innovative Spinal Cord Implant Procedure
Professor Tal Dvir, head of the Sagol Centre for Regenerative Biotechnology and the Nanotechnology Centre at Tel Aviv University, leads this revolutionary effort. He also serves as chief scientist at Matricelf, the company commercializing this technology. Unlike other tissues, spinal cord neurons lack natural regenerative capacity, and scar tissue often obstructs remaining signals over time. Therefore, this novel procedure seeks to replace the damaged segment with a lab-grown spinal cord, designed to seamlessly fuse with healthy tissue above and below the injury. This innovation originated approximately three years ago when Professor Dvir’s lab successfully engineered a personalized three-dimensional human spinal cord in vitro. Findings, published in Advanced Science, revealed remarkable results: mice with chronic paralysis regained mobility after receiving these engineered implants.
The process begins with the patient’s own blood cells. These cells are meticulously reprogrammed into stem-cell-like cells, which possess the unique ability to develop into any cell type. Concurrently, fat tissue is collected from the patient to construct a customized hydrogel scaffold. Within this scaffold, the stem-like cells are guided to develop into a spinal cord structure. Once engineered, this tissue is implanted, replacing scarred areas and re-establishing connections within the nervous system. The goal is to restore the severed electrical pathway, enabling signal transmission and ultimately, movement.
Regulatory Approval and National Significance
A few months ago, Professor Dvir and his team secured preliminary approval from Israel’s Ministry of Health for compassionate use trials involving eight patients. Significantly, this makes Israel the first nation to undertake this pioneering procedure. This development justly instills national pride. Professor Dvir emphasized that his team developed the technology entirely in Israel, at Tel Aviv University and Matricelf, with the explicit intention that the initial surgery would be performed in Israel on an Israeli patient. Matricelf commercialized the technology, a company established in 2019 under a licensing agreement with Tel Aviv University’s technology transfer company, Ramot.
Matricelf’s Vision for Spinal Cord Repair
Gil Hakim, CEO of Matricelf, stated that this milestone signifies a crucial transition from groundbreaking research to direct patient treatment. Utilizing each patient’s own cells effectively eliminates key safety risks, positioning Matricelf at the vanguard of regenerative medicine. Furthermore, this initial procedure transcends a mere scientific breakthrough; it represents a tangible step toward transforming a medical field long considered untreatable. Hakim elaborated that, if successful, this therapy could establish a new standard of care in spinal cord repair, addressing a multi-billion-dollar market currently devoid of effective solutions. Matricelf expresses immense pride in Israel leading this global endeavor and remains fully committed to delivering this innovation to patients worldwide. Professor Dvir reiterates their ultimate objective: to help paralyzed patients rise from their wheelchairs. The extraordinary success witnessed in animal model trials fuels optimism that human results will prove equally promising. Consequently, the world watches eagerly as this historic surgery approaches.
Frequently Asked Questions
Q1: What is unique about Israel’s upcoming spinal cord implant surgery?
This surgery marks the world’s first human spinal cord implant using the patient’s own cells, which minimizes rejection risks. It aims to replace damaged spinal cord sections with lab-grown tissue designed to integrate with existing healthy tissue, potentially restoring mobility. [4, 8, 14, 16]
Q2: Who developed this pioneering spinal cord implant technology?
Professor Tal Dvir, leading the Sagol Centre for Regenerative Biotechnology and the Nanotechnology Centre at Tel Aviv University, developed this technology. His team, in collaboration with Matricelf, an Israeli biotech company, is commercializing this innovative treatment. [4, 5, 6, 11, 12, 14, 15, 16]
Q3: What are the expected outcomes of this spinal cord implant?
Based on highly successful animal studies where paralyzed mice regained their ability to walk, researchers hope this human implant will enable paralyzed patients to stand and walk again. This therapy could define a new standard of care for spinal cord repair. [4, 5, 8, 11, 14, 15]
References
- World’s first human spinal cord implant to take place in Israel – ETHealthworld
- The Latest Advances in Spinal Cord Injury Treatment: National Services Bringing Hope Nationwide
- Israel to carry out world’s first spinal cord transplant | The Jerusalem Post
- Tel Aviv University researchers engineer human spinal cord implants for treating paralysis
- Blue-and-white breakthrough: Israel to perform first-ever transplant of lab-grown spinal cord
- Recent Advances in the Treatment of Spinal Cord Injury – PMC – PubMed Central
- Israel to launch world’s first human spinal cord transplant using patient’s own cells
- Advances and Challenges in Spinal Cord Injury Treatments – PMC – PubMed Central
- Israeli Scientific Breakthrough: A Potential Treatment for Paralysis – Gov.il
- About us – Matricelf
- Israeli biotech company to conduct first human transplant of lab-grown spinal cord
- TAU Breakthrough Offers New Hope to Help People With Paralysis Walk Again | Tel Aviv University
- The first human spinal cord repair using the patient own cells – EurekAlert!
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.